Terms: = Prostate cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
32 results:
1. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.
Kwan KH; Burvenich IJG; Centenera MM; Goh YW; Rigopoulos A; Dehairs J; Swinnen JV; Raj GV; Hoy AJ; Butler LM; Scott AM; White JM; Ackermann U
Nucl Med Biol; 2021 Feb; 93():37-45. PubMed ID: 33310350
[TBL] [Abstract] [Full Text] [Related]
3. Overall Survival After Treatment of Localized prostate cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy.
Liu Y; Patel SA; Jani AB; Gillespie TW; Patel PR; Godette KD; Hershatter BW; Shelton JW; McDonald MW
Clin Genitourin Cancer; 2021 Jun; 19(3):255-266.e7. PubMed ID: 32972877
[TBL] [Abstract] [Full Text] [Related]
4. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant prostate cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract] [Full Text] [Related]
5. Androgens and Overall Survival in Patients With Metastatic Castration-resistant prostate cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract] [Full Text] [Related]
6. prostate Specific Antigen (PSA) as Predicting Marker for clinical outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk prostate cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract] [Full Text] [Related]
7. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal prostate cancer.
Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
[TBL] [Abstract] [Full Text] [Related]
8. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant prostate cancer Pretreated With Docetaxel Chemotherapy: A prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
9. PTEN Loss Is Associated with Worse outcome in HER2-Amplified Breast cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract] [Full Text] [Related]
10. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract] [Full Text] [Related]
11. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.
Spaliviero M; Dalbagni G; Bochner BH; Poon BY; Huang H; Al-Ahmadie HA; Donahue TF; Taylor JM; Meeks JJ; Sjoberg DD; Donat SM; Reuter VE; Herr HW
J Urol; 2014 Sep; 192(3):702-7. PubMed ID: 24603101
[TBL] [Abstract] [Full Text] [Related]
13. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.
Lahmer G; Lotter M; Kreppner S; Fietkau R; Strnad V
Strahlenther Onkol; 2013 Aug; 189(8):668-74. PubMed ID: 23824103
[TBL] [Abstract] [Full Text] [Related]
14. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Verhoven B; Yan Y; Ritter M; Khor LY; Hammond E; Jones C; Amin M; Bahary JP; Zeitzer K; Pollack A
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):317-23. PubMed ID: 23474109
[TBL] [Abstract] [Full Text] [Related]
15. The clinical impact of uncertainties in the mean excitation energy of human tissues during proton therapy.
Besemer A; Paganetti H; Bednarz B
Phys Med Biol; 2013 Feb; 58(4):887-902. PubMed ID: 23337713
[TBL] [Abstract] [Full Text] [Related]
16. clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
[TBL] [Abstract] [Full Text] [Related]
17. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.
Keshari KR; Tsachres H; Iman R; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2011 Jul; 24(6):691-9. PubMed ID: 21793074
[TBL] [Abstract] [Full Text] [Related]
18. outcomes after prostate brachytherapy are even better than predicted.
Frank SJ; Levy LB; van Vulpen M; Crook J; Sylvester J; Grimm P; Pugh TJ; Swanson DA
Cancer; 2012 Feb; 118(3):839-47. PubMed ID: 21751187
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide association study identifies new prostate cancer susceptibility loci.
Schumacher FR; Berndt SI; Siddiq A; Jacobs KB; Wang Z; Lindstrom S; Stevens VL; Chen C; Mondul AM; Travis RC; Stram DO; Eeles RA; Easton DF; Giles G; Hopper JL; Neal DE; Hamdy FC; Donovan JL; Muir K; Al Olama AA; Kote-Jarai Z; Guy M; Severi G; Grönberg H; Isaacs WB; Karlsson R; Wiklund F; Xu J; Allen NE; Andriole GL; Barricarte A; Boeing H; Bueno-de-Mesquita HB; Crawford ED; Diver WR; Gonzalez CA; Gaziano JM; Giovannucci EL; Johansson M; Le Marchand L; Ma J; Sieri S; Stattin P; Stampfer MJ; Tjonneland A; Vineis P; Virtamo J; Vogel U; Weinstein SJ; Yeager M; Thun MJ; Kolonel LN; Henderson BE; Albanes D; Hayes RB; Feigelson HS; Riboli E; Hunter DJ; Chanock SJ; Haiman CA; Kraft P
Hum Mol Genet; 2011 Oct; 20(19):3867-75. PubMed ID: 21743057
[TBL] [Abstract] [Full Text] [Related]
20. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
[TBL] [Abstract] [Full Text] [Related]
[Next]
